|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While 23 % of SCC tumors harbored a PIK3CA mutation, all BSCC cases were wild-type for PIK3CA (p = 0.002), and there were no differences in p53 expression between BSCCs and SCCs (p = 0.57), as assessed by immunohistochemistry.
|
25691283 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Whether they function as direct precursors to a less common form of squamous cell carcinoma will require further study, but carcinomas associated with these lesions might warrant testing for PIK3CA mutations to address this question.
|
27834349 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We therefore screened 61 non-melanoma skin cancer samples (30 SCC and 31 BCC) for the presence of activating PIK3CA and AKT1 mutations.
|
20557351 |
2010 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We therefore analyzed 102 large-cell carcinomas by immunohistochemistry for TTF-1 and ΔNp63/p40 as classifiers for adenocarcinoma and squamous cell carcinoma, respectively, and correlated the resulting subtypes with nine therapeutically relevant genetic alterations characteristic of adenocarcinoma (EGFR, KRAS, BRAF, MAP2K1/MEK1, NRAS, ERBB2/HER2 mutations and ALK rearrangements) or more common in squamous cell carcinoma (PIK3CA and AKT1 mutations).
|
23196793 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have studied the prognostic importance of PIK3CA mutations as well as the relation to other markers in a large number of early stage lung cancers of squamous carcinoma subtype.
|
28024696 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using samples from 122 patients, we established 41 NSCLC PDXs [30 adenocarcinoma (AD), 11 squamous cell carcinoma (SQ)], among which the following driver mutation were observed: 13 EGFR-mutant, 4 ALK-rearrangement, 1 ROS1-rearrangement, 1 PIK3CA-mutant, 1 FGFR1-amplification, and 2 KRAS-mutant.
|
30268457 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Upregulation of circulating PI3K p110α isoform and its direct correlation with increasing tumor load in OSCC patients indicates that it may be a significant prognostic indicator and a suitable target for therapeutic/chemo-preventive strategies for tobacco-related OSCC.
|
23228846 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two novel oncogenes, namely squamous cell carcinoma (SCC)-related oncogene (SCCRO) and PIK3CA (gene encoding phosphatidylinositol-3 kinase catalytic alpha-polypeptide), have been identified as targets of 3q26.3 amplification.
|
12796399 |
2003 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway.
|
31638186 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Transformed SCC acquired genomic alterations related to the PI3K/AKT/mTOR pathway, in addition to the initial EGFR mutation.
|
31319998 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This prompts us to pursue 3q26 (or PIK3CA) prognostic evaluation in a larger population of head and neck squamous cell carcinomas.
|
11358835 |
2001 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This may be because pathways enriched in the TrkB high expressers, like those involving oncogenes NFE2L2, PIK3CA, and SOX2, are known to have SCC anatomic site-specific effects on progression.
|
31221127 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings offer a novel strategy that could potentially enhance the efficacy of PI3Kα inhibitors while mitigating dose-limiting toxicity in patients with head and neck squamous cell carcinomas.
|
28194032 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The majority of OSCC cell lines showed an activation of PI3K/Akt signaling, and enforced expression of NDRG2 in HSC-3 cells decreased the level of phosphorylated Akt at Serine 473 (p-Akt).
|
20045673 |
2010 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The knowledge of the PIK3CA's involvement in OSCC is important because a specific kinase inhibitor could be considered as a future therapeutic option for OSCC patients with PIK3CA mutations.
|
21824802 |
2011 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The immunoregulatory protein B7-H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K/Akt/mTOR pathway.
|
31737114 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression of PIK3CA was increased in OSCC tumors; however, none of the nine tested SNPs of PIK3CA was associated with susceptibility to OSCC in the studied population.
|
26722541 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to investigate how alterations in the PI3K pathway correlate with non-small cell lung cancer subtypes squamous cell carcinoma (SSC) and adenocarcinoma (ADCA).
|
24500884 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The activated pathway in lung ADC and SCC mainly focuses on MAPK and PI3K with different key genes of each, respectively, and the activated pathway of SCLC mainly focuses on JAK-STAT pathway.
|
27845189 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway is frequently activated in various squamous cell carcinomas (SCCs).
|
30568499 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PIK3CA was amplified in 70% of squamous carcinomas, 38% of large cell carcinomas, 19% of adenocarcinomas, and 67% of small cell lung cancers.
|
15317667 |
2004 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting the PI3K-AKT-mTOR and/or cyclin pathway components in SCC may be warranted.
|
26030731 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synchronous lung cancers from 60 patients (42 with adenocarcinoma and 18 with squamous cell carcinoma), clinically considered to represent intrapulmonary metastases, were histologically subtyped according to the 2015 World Health Organization classification of lung tumors and subjected to genotypic analysis (KRAS, EGFR, BRAF, PIK3CA, ALK, MET and ROS1 in adenocarcinoma and PIK3CA and p16 in squamous cell carcinoma).
|
27080983 |
2016 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silencing Kif2a induces apoptosis in squamous cell carcinoma of the oral tongue through inhibition of the PI3K/Akt signaling pathway.
|
24248467 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PTEN (16.1%), STK11 (8.3%), and PIK3CA (7.2%) were the three most frequently enriched genes in smokers with SCC.
|
22768234 |
2012 |